SCHEMBL84409

SCHEMBL84409

CC(C)c1cnc(N)c(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
ALOX12 P18054 2/20 0.44
HTT P42858 2/20 0.44
HIF1A Q16665 2/20 0.44
GAA P10253 1/20 0.44
GABRA1 P14867 1/20 0.41
GABRB2 P47870 1/20 0.41
TRPA1 O75762 1/20 0.41
PTGS1 P23219 1/20 0.41
CACNA1C Q13936 1/20 0.41
USP7 Q93009 1/20 0.37
TYR P14679 3/20 0.36
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
DHFR P00374 1/20 0.34
TDP1 Q9NUW8 5/20 0.33
KDM4E B2RXH2 5/20 0.33
RECQL P46063 4/20 0.33
MAPT P10636 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12381069 0.78 TRPA1 (0.43) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL15471948 0.78 HTT (0.42) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL18719676 0.77 GABRA1 (0.36) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL17953260 0.77 GABRA1 (0.38) GABRA1GABRB2NOS3NOS1NOS2
SCHEMBL16248205 0.77 GABRA1 (0.42) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL29910000 0.77 GABRA1 (0.38) GABRA1GABRB2NOS3NOS1NOS2
SCHEMBL84407 0.77 NOS3 (0.56) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL12197724 0.77 TRPA1 (0.47) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL30867968 0.75 NOS3 (0.34) ALDH1A1ALOX12HTTHIF1AGAA
SCHEMBL21206568 0.75 HTT (0.54) ALDH1A1ALOX12HTTHIF1AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS ALDH1A1 3257/4885ALOX12 4156/4885HTT 2408/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS ALDH1A1 2358/4885ALOX12 3761/4885HTT 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.